NUC-8232
Various Solid Tumors
Key Facts
About NuCana
NuCana's mission is to significantly improve survival outcomes for cancer patients by leveraging its proprietary ProTide technology platform to develop next-generation chemotherapy agents. The company has advanced multiple candidates into clinical development, with its lead programs, NUC-3373 and NUC-7738, demonstrating clinical activity and favorable safety profiles in mid-stage trials. NuCana's strategy involves applying its phosphoramidate chemistry to overcome the pharmacological limitations of established nucleoside analogs, thereby creating new standards of care. Despite promising science, the company faces significant financial and clinical execution risks as it seeks to advance its pipeline towards pivotal studies.
View full company profileTherapeutic Areas
Other Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| TCR Library Program | Medigene | Discovery |
| Solid Tumor Profiling | Diatech Pharmacogenetics | Commercial |
| BAVENCIO (avelumab) | EMD Serono | Approved |
| Jemperli (dostarlimab) combinations | GSK | Phase 3 |
| FoundationOne®CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| FoundationOne®Liquid CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| Taiho Oncology Pipeline | Otsuka Holdings | Multiple (I-III) |
| Lenvatinib + Pembrolizumab | Eisai | Phase 3 / Marketed |
| PD-1/PD-L1 Inhibitor | PeptiDream | Phase 1 |
| Cadonilimab (AK104) | Akeso | Phase III |
| TEVIMBRA (tislelizumab) | BeOne Medicines | Approved / Phase 3 |
| Early I-O Pipeline | Ipsen | Pre-clinical / Phase 1 |